Degludec

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 957 publications

Pharmacokinetics, Clinical Efficacy, and Safety of Once-Weekly Insulin Icodec: A Structured Narrative Review (2022-2026).

Pharmacokinetics, Clinical Efficacy, and Safety of Once-Weekly Insulin Icodec: A Structured Narrative Review (2022-2026).

Journal: Cureus

Published: July 28, 2026

The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity.

The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity.

Journal: Pharmacological research

Published: July 27, 2026

Once-Weekly Subcutaneous Insulin Efsitora for the Management of Diabetes Mellitus: A Systematic Review and Meta-Analysis Study.

Once-Weekly Subcutaneous Insulin Efsitora for the Management of Diabetes Mellitus: A Systematic Review and Meta-Analysis Study.

Journal: Medeniyet medical journal

Published: July 01, 2026

The coming of weekly insulin.

The coming of weekly insulin.

Journal: Expert opinion on pharmacotherapy

Published: June 11, 2026

Design and Evaluation of a Novel Clinical Decision Support Algorithm for Weekly Insulin Efsitora Alfa.

Design and Evaluation of a Novel Clinical Decision Support Algorithm for Weekly Insulin Efsitora Alfa.

Journal: Journal of diabetes science and technology

Published: June 08, 2026

Efficacy and safety of insulin icodec compared with insulin efsitora in patients with type 2 diabetes: a systematic review and network meta-analysis.

Efficacy and safety of insulin icodec compared with insulin efsitora in patients with type 2 diabetes: a systematic review and network meta-analysis.

Journal: Frontiers in endocrinology

Published: June 07, 2026

Projecting the Long-Term Cost-Effectiveness of Once-Weekly Insulin Icodec Versus Once-Daily Basal Insulin Analogs in Italy Using the Prime T2D Model.

Projecting the Long-Term Cost-Effectiveness of Once-Weekly Insulin Icodec Versus Once-Daily Basal Insulin Analogs in Italy Using the Prime T2D Model.

Journal: Diabetes, obesity & metabolism

Published: May 27, 2026

Efficacy and Safety of iGlarLixi Versus IDegAsp by Baseline Age, Disease Duration and HbA1c in Chinese People With Type 2 Diabetes: Post Hoc Analyses of the Soli-D Study.

Efficacy and Safety of iGlarLixi Versus IDegAsp by Baseline Age, Disease Duration and HbA1c in Chinese People With Type 2 Diabetes: Post Hoc Analyses of the Soli-D Study.

Journal: Diabetes, obesity & metabolism

Published: May 06, 2026

Rapid and comprehensive identification of the metabolic soft spots of peptide drugs with highly cross-linked disulfide bonds by integrating established proteomic workflow with a product ion filtering strategy.

Rapid and comprehensive identification of the metabolic soft spots of peptide drugs with highly cross-linked disulfide bonds by integrating established proteomic workflow with a product ion filtering strategy.

Journal: Drug metabolism and disposition: the biological fate of chemicals

Published: April 29, 2026

Evaluating once-weekly insulin efsitora alfa for adults with type 2 diabetes.

Evaluating once-weekly insulin efsitora alfa for adults with type 2 diabetes.

Journal: Expert opinion on pharmacotherapy

Published: April 28, 2026

A paradigm shift in diabetes care: clinical implications of once-weekly insulin icodec.

A paradigm shift in diabetes care: clinical implications of once-weekly insulin icodec.

Journal: Annals of medicine and surgery (2012)

Published: April 12, 2026

Insulin Efsitora Versus Degludec in Adults with Type 2 Diabetes Using Basal Insulin: QWINT-3 Japan Subgroup Analysis.

Insulin Efsitora Versus Degludec in Adults with Type 2 Diabetes Using Basal Insulin: QWINT-3 Japan Subgroup Analysis.

Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders

Published: April 08, 2026

Showing 1-12 of 957

Last Updated: 09/26/2026